AR062786A1 - Benzoxasoles 2-7-disustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y usos como agentes antiproliferativos. - Google Patents

Benzoxasoles 2-7-disustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y usos como agentes antiproliferativos.

Info

Publication number
AR062786A1
AR062786A1 ARP070104060A ARP070104060A AR062786A1 AR 062786 A1 AR062786 A1 AR 062786A1 AR P070104060 A ARP070104060 A AR P070104060A AR P070104060 A ARP070104060 A AR P070104060A AR 062786 A1 AR062786 A1 AR 062786A1
Authority
AR
Argentina
Prior art keywords
unsubstituted
alkyl
benzoxasols
preparation
disposed
Prior art date
Application number
ARP070104060A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37717673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR062786(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR062786A1 publication Critical patent/AR062786A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de los mismos -solos o en combinacion con uno o más compuestos farmacéuticamente activos diferentes- para el tratamiento en especial de una enfermedad mediada por la cinasa de proteína tirosina (tal como una enfermedad tumoral) o para la fabricacion de una preparacion farmacéutica para utilizarse en el tratamiento de esta enfermedad. Reivindicacion 1: Un compuesto de la formula (1) en donde X es N o CR5; en donde R5 es halogeno, ciano, hidroxilo, alcoxilo C1-7, alquilo C1-7, amino, N-mono- o N,N-di-alquilo C1-7 o de preferencia H; R1 es arilo insustituido o sustituido o es heterociclilo insustituido o sustituido; y R2 es arilo insustituido o sustituido o es heterociclilo insustituido o sustituido, el cual está enlazado por medio de un átomo de C del anillo; R3 es ciano, hidroxilo, alquilo C1-7, amino, N-mono- o N,N-di-alquilo C1-7 o de preferencia H; y R4 es hidroxilo, amino o de preferencia H; o sales del mismo.
ARP070104060A 2006-09-15 2007-09-13 Benzoxasoles 2-7-disustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y usos como agentes antiproliferativos. AR062786A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06120733A EP1900729A1 (en) 2006-09-15 2006-09-15 Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors

Publications (1)

Publication Number Publication Date
AR062786A1 true AR062786A1 (es) 2008-12-03

Family

ID=37717673

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104060A AR062786A1 (es) 2006-09-15 2007-09-13 Benzoxasoles 2-7-disustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y usos como agentes antiproliferativos.

Country Status (30)

Country Link
US (1) US8629168B2 (es)
EP (2) EP1900729A1 (es)
JP (1) JP5325105B2 (es)
KR (1) KR20090064389A (es)
CN (1) CN101516860B (es)
AR (1) AR062786A1 (es)
AT (1) ATE532774T1 (es)
AU (1) AU2007296916B2 (es)
BR (1) BRPI0716841A2 (es)
CA (1) CA2660987A1 (es)
CL (1) CL2007002669A1 (es)
CO (1) CO6150142A2 (es)
CR (1) CR10639A (es)
EA (1) EA200900388A1 (es)
ES (1) ES2377148T3 (es)
GT (1) GT200900056A (es)
IL (1) IL196860A0 (es)
MA (1) MA30723B1 (es)
MX (1) MX2009002812A (es)
NO (1) NO20091469L (es)
PA (1) PA8748101A1 (es)
PE (1) PE20080842A1 (es)
PL (1) PL2066647T3 (es)
PT (1) PT2066647E (es)
SM (1) SMP200900023B (es)
TN (1) TN2009000070A1 (es)
TW (1) TW200819444A (es)
UY (1) UY30587A1 (es)
WO (1) WO2008031594A1 (es)
ZA (1) ZA200900477B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
EP2313414B1 (en) 2008-07-08 2015-11-04 Intellikine, LLC Kinase inhibitors and methods of use
CA2730843A1 (en) * 2008-07-15 2010-01-21 Sanofi-Aventis Oxazolopyrimidines as edg-1 receptor agonists
EP2323978A1 (en) * 2008-08-12 2011-05-25 Takeda Pharmaceutical Company Limited Amide compound
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EA021367B1 (ru) 2008-11-28 2015-06-30 Кова Компани, Лтд. Производное пиридин-3-карбоксамида
JPWO2011078360A1 (ja) 2009-12-24 2013-05-09 武田薬品工業株式会社 アミド化合物
AR079980A1 (es) * 2010-01-13 2012-03-07 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2,5,7
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
CN103102359B (zh) * 2011-11-15 2016-11-09 江苏先声药业有限公司 嘧啶类化合物及其应用
AU2012345732B2 (en) 2011-11-30 2016-07-14 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
WO2014075318A1 (zh) * 2012-11-19 2014-05-22 江苏先声药业有限公司 嘧啶类化合物及其应用
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
CN106132406B (zh) 2014-02-03 2020-03-27 夸德里加生物科学公司 作为化疗剂的β-取代的γ-氨基酸和类似物
CN106163509B (zh) 2014-02-03 2019-05-03 夸德里加生物科学公司 作为化疗剂的β-取代的β-氨基酸及类似物
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
EP3331851A1 (en) 2015-08-03 2018-06-13 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof
TW202307005A (zh) 2021-05-28 2023-02-16 美商邊際分析公司 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006227B1 (ru) * 1999-12-10 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP1674467A1 (en) * 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
AU2006286573B2 (en) * 2005-09-02 2012-05-31 F. Hoffmann-La Roche Ag Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
MX2009000769A (es) * 2006-07-21 2009-01-28 Novartis Ag Compuestos de 2,4-di(arilaminio)-pirimidin-5-carboxamida como inhibidores de cinasas jak.

Also Published As

Publication number Publication date
PE20080842A1 (es) 2008-08-11
PT2066647E (pt) 2012-01-17
AU2007296916B2 (en) 2011-10-06
ZA200900477B (en) 2010-01-27
US20100009978A1 (en) 2010-01-14
ATE532774T1 (de) 2011-11-15
MA30723B1 (fr) 2009-09-01
SMAP200900023A (it) 2009-05-11
UY30587A1 (es) 2008-05-02
SMP200900023B (it) 2009-07-14
PA8748101A1 (es) 2009-08-26
BRPI0716841A2 (pt) 2013-10-01
JP5325105B2 (ja) 2013-10-23
CA2660987A1 (en) 2008-03-20
EP1900729A1 (en) 2008-03-19
EP2066647B1 (en) 2011-11-09
MX2009002812A (es) 2009-03-31
CO6150142A2 (es) 2010-04-20
JP2010503629A (ja) 2010-02-04
GT200900056A (es) 2011-11-08
EP2066647A1 (en) 2009-06-10
CR10639A (es) 2009-07-03
CL2007002669A1 (es) 2008-05-09
TN2009000070A1 (en) 2010-08-19
WO2008031594A1 (en) 2008-03-20
IL196860A0 (en) 2009-11-18
EA200900388A1 (ru) 2009-08-28
TW200819444A (en) 2008-05-01
KR20090064389A (ko) 2009-06-18
ES2377148T3 (es) 2012-03-22
CN101516860A (zh) 2009-08-26
CN101516860B (zh) 2012-06-27
NO20091469L (no) 2009-04-15
AU2007296916A1 (en) 2008-03-20
US8629168B2 (en) 2014-01-14
PL2066647T3 (pl) 2012-04-30

Similar Documents

Publication Publication Date Title
AR062786A1 (es) Benzoxasoles 2-7-disustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y usos como agentes antiproliferativos.
UY29301A1 (es) Derivados amida
CL2009001274A1 (es) Compuestos derivados de triazina sustituida, mediados por la inhibicion de la kinasa p13 y mtor; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de diferentes tipos de cancer.
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
DOP2010000320A (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
AR066014A1 (es) Difenil- dihidro -imidazopiridinonas. composiciones farmaceuticas y usos.
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
AR050932A1 (es) Amidas biciclicas como inhibidores de cinasa
SV2007002202A (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan ref. pc32310a
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
ECSP10010599A (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
AR059064A1 (es) Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.
UY29177A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
ECSP10010722A (es) Compuestos orgánicos
AR056888A1 (es) Derivados de heterociclil imidazol
EA200970047A1 (ru) Водные суспензии тмс278
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
UY30127A1 (es) Derivados de acidos antranilicos fenoxi y feniltio, composiciones farmaceuticas que los contienen y su uso.

Legal Events

Date Code Title Description
FB Suspension of granting procedure